Content area

|
|

Cancerimmunterapi

Forfatter(e)

Julie Westerlin Kjeldsen1, 2, Marco Donia1, 2 & Inge Marie Svane1, 2

1) Center for Cancer Immun Terapi, Hæmatologisk Afdeling, Herlev Hospital 2) Onkologisk Afdeling, Herlev Hospital Ugeskr Læger 2018;180:V09170691

Reference: 
Ugeskr Læger 2018;180:V09170691
Blad nummer: 
Sidetal: 
2-6
Cancer immunotherapy

Cancer immunotherapy takes advantage of the immune system to treat cancer. The checkpoint inhibitors have advanced the field of cancer treatment, but adoptive cell therapy and cancer vaccines also show promising results. The checkpoint inhibitors ipilimumab and later nivolumab/pembrolizumab have been standard therapy to patients with metastatic melanoma for several years. Today, the field is expanding, and other types of solid tumours have had checkpoint inhibitors applied to them, and more will follow. A portion of the patients develop immune-related adverse events, which should be handled by specialists.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Lenette Tove Bech | 21/10
1 Kommentar
af Thor Andersen Knudsen | 21/10
6 kommentarer
af Jørn Rosborg | 21/10
1 Kommentar
af Merethe Kirstine Kousgaard Andersen | 21/10
9 kommentarer
af Thor Andersen Knudsen | 21/10
1 Kommentar
af Lars Ulrik Gerdes | 20/10
1 Kommentar
af Nina Tejs Jørring | 19/10
2 kommentarer
af Merete Stampe Mølberg | 18/10
2 kommentarer
af Susanne Mejlby Nielsen | 18/10
4 kommentarer